Phosphoinositide 3-kinase (PI3K) Inhibitors
Customize your policy alerts
Sign up for Premera Bluecross Policy 5.01.592 alerts
Get alerted when Policy 5.01.592 changes without checking for updates manually.
Monitor payer policy activity
This policy establishes medical-necessity and prior-authorization criteria for selected PI3K, AKT, and related pathway inhibitors used for specified cancers, activated PI3K delta syndrome, and PIK3CA-related overgrowth spectrum. Oral drugs are managed through the pharmacy benefit.
Added coverage criteria for Itovebi (inavolisib).
Added Truqap (capivasertib) coverage criteria for certain individuals with breast cancer and metastatic PTEN-deficient prostate cancer.
Added Joenja (leniolisib) coverage criteria for activated phosphoinositide 3-kinase delta syndrome.
Added coverage for Vijoice and Piqray for PIK3CA-related overgrowth spectrum and revised Piqray breast cancer criteria.
Changed initial authorization for all other reviews of listed oral drugs from 3 months to 6 months.
Removed coverage for Ukoniq, Aliqopa, duvelisib in relapsed or refractory follicular lymphoma, and selected idelalisib and copanlisib indications.
Removed HCPCS code J9057.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.